Reduced brain delivery of homovanillic acid to cerebrospinal fluid during human aging

Archives of Neurology

Volumn 61, Issue 11, 2004, Pages 1721-1724

  Rapoport, Stanley I ^a   Schapiro, Mark B ^a,b   May, Conrad ^a,c  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOVANILLIC ACID;

ADULT; AGED; AGING; ARTICLE; BRAIN LEVEL; CEREBROSPINAL FLUID FLOW; CEREBROSPINAL FLUID LEVEL; CISTERNA MAGNA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; LUMBAR SPINAL CORD; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SUBARACHNOID SPACE;

ADULT; AGED; AGED, 80 AND OVER; AGING; BLOOD-BRAIN BARRIER; BRAIN CHEMISTRY; FEMALE; HOMOVANILLIC ACID; HUMANS; MALE; RECEPTORS, DOPAMINE;

EID: 7744231638     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.61.11.1721     Document Type: Article

References (29)

1. Wong DF, Wagner HN Jr, Dannals RF, et al. Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science. 1984;226:1393-1396.
2. Ma SY, Ciliax BJ, Stebbins G, et al. Dopamine transporter-immunoreactive neurons decrease with age in the human substantia nigra. J Comp Neurol. 1999;409:25-37.
3. Kish SJ, Shannak K, Rajput A, Deck JH, Hornykiewicz O. Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease. J Neurochem. 1992;58:642-648.
4. Gottfries CG, Gottfries I, Johansson B, et al. Acid monoamine metabolites in human cerebrospinal fluid and their relations to age and sex. Neuropharmacology. 1971;10:665-672.
5. Palmer AM, Sims NR, Bowen DM, et al. Monoamine metabolite concentrations in lumbar cerebrospinal fluid of patients with histologically verified Alzheimer's dementia. J Neurol Neurosurg Psychiatry. 1984;47:481-484.
6. Tohgi H, Takahashi S, Abe T. The effect of age on concentrations of monoamines, amino acids, and their related substances in the cerebrospinal fluid. J Neural Transm Park Dis Dement Sect. 1993;5:215-226.
7. Hartikainen P, Soininen H, Reinikainen KJ, Sirvio J, Soikkeli R, Riekkinen PJ. Neurotransmitter markers in the cerebrospinal fluid of normal subjects: effects of aging and other confounding factors. J Neural Transm Gen Sect. 1991;84:103-117.
8. Bartholini G, Pletscher A, Tissot R. On the origin of homovanillic acid in the cerebrospinal fluid. Experientia. 1966;22:609-610.
9. Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev. 1966;18:925-964.
10. Post RM, Goodwin FK, Gordon E, Watkin DM. Amine metabolites in human cerebrospinal fluid: effects of cord transection and spinal fluid block. Science. 1973;179:897-899.
11. Masserman JH. Cerebrospinal hydrodynamics, IV: clinical experimental studies. Arch Neurol Psychiatr. 1934;32:523-553.
12. May C, Kaye JA, Atack JR, Schapiro MB, Friedland RP, Rapoport SI. Cerebrospinal fluid production is reduced in healthy aging. Neurology. 1990;40:500-503.
13. Czosnyka M, Czosnyka ZH, Whitfield PC, Donovan T, Pickard JD. Age dependence of cerebrospinal pressure-volume compensation in patients with hydrocephalus. J Neurosurg. 2001;94:482-486.
14. Preston JE. Ageing choroid plexus-cerebrospinal fluid system. Microsc Res Tech. 2001;52:31-37.
15. Yuwiler A, Bennett BL, Geller E. Is there a probenecid sensitive transport system for monoamine catabolites at the level of the brain capillary plexus? Neurochem Res. 1982;7:1277-1285.
16. Scheinin H, Scheinin M. Repetitive measurement of monoamine metabolite levels in cerebrospinal fluid of conscious rats: effects of reserpine and haloperidol. Eur J Pharmacol. 1985;113:345-351.
17. Wood JH. Physiology, pharmacology, and dynamics of cerebrospinal fluid. In: Wood JH, ed. Neurobiology of Cerebrospinal Fluid. Vol 1. New York, NY: Plenum; 1980:1-16.
18. Kety SS. The theory and applications of the exchange of inert gas at the lungs and tissues. Pharmacol Rev. 1951;3:1-41.
19. Rapoport SI. Blood-Brain Barrier in Physiology and Medicine. New York, NY: Raven Press; 1976.
20. Van der Poel FW, Van Praag HM, Korf J. Evidence for a probenecid-sensitive transport system of acid monoamine metabolites from the spinal subarachnoid space. Psychopharmacology (Berl). 1977;52:35-40.
21. Johansson B, Roos BE. Concentrations of monoamine metabolites in human lumbar and cisternal cerebrospinal fluid. Acta Neurol Scand. 1975;52:137-144.
22. Degrell I, Nagy E. Correlations between cisternal CSF and plasma concentrations of HVA, MHPG, 5-HIAA, DA, and NA. Biol Psychiatry. 1990;27:1179-1182.
23. LeWitt PA, Galloway MP, Matson W, et al. Markers of dopamine metabolism in Parkinson's disease: the Parkinson Study Group. Neurology. 1992;42:2111-2117.
24. Hildebrand J, Moussa Z, Raftopoulos C, Vanhouche J, Laute MA, Przedborski S. Variations of homovanillic acid levels in ventricular cerebrospinal fluid. Acta Neurol Scand. 1992;85:340-342.
25. Silverberg GD, Heit G, Huhn S, et al. The cerebrospinal fluid production rate is reduced in dementia of the Alzheimer's type. Neurology. 2001;57:1763-1766.
26. Lambert GW, Eisenhofer G, Cox HS, et al. Direct determination of homovanillic acid release from the human brain, an indicator of central dopaminergic activity. Life Sci. 1991;49:1061-1072.
27. Kopin IJ, Oliver JA, Polinsky RJ. Relationship between urinary excretion of homovanillic acid and norepinephrine metabolites in normal subjects and patients with orthostatic hypotension. Life Sci. 1988;43:125-131.
28. Mori S, Takanaga H, Ohtsuki S, et al. Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells. J Cereb Blood Flow Metab. 2003;23:432-440.
29. Volicer L, Direnfeld LK, Langlais PJ, Freedman M, Bird ED, Albert ML. Catecholamine metabolites and cyclic nucleotides in cerebrospinal fluid in dementia of Alzheimer type. J Gerontol. 1985;40:708-713.